Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01530022 · ClinicalTrials.gov registry record · Phase 1
Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects
A Phase 1 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01530022 is a Phase 1 study that has completed, run by UCB Pharma. The registered enrollment target is 60 participants.
The verdict
NCT01530022, a Phase 1 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The primary objective of this Phase 1 crossover study is to evaluate the neuropsychological effects of Lacosamide (LCM) compared to Carbamazepine Immediate Release (CBZ-IR) after administration in healthy subjects. Safety, tolerability, and pharmacokinetic data will also be collected.
Interventions
- DRUG Lacosamide (LCM)
- DRUG Carbamazepine Immediate Release (CBZ-IR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-05 |
| Est. Completion | 2014-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01530022
The ClinicalTrials.gov registry entry for NCT01530022 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lacosamide (LCM) is the first listed.
NCT01530022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01530022 about?
NCT01530022 is a clinical study titled "Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects". The primary objective of this Phase 1 crossover study is to evaluate the neuropsychological effects of Lacosamide (LCM) compared to Carbamazepine Immediate Release (CBZ-IR) after administration in healthy subjects. Safety, tolerability, and pharmacokinetic data will also be collected.
What is the current status of trial NCT01530022?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2012-05. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01530022?
The interventions under investigation include: Lacosamide (LCM) (DRUG), Carbamazepine Immediate Release (CBZ-IR) (DRUG).
Who is sponsoring clinical trial NCT01530022?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.